Southwest Foundation for Biomedical Research

Rampratap Kushwaha

Patrick Kanda

Henry C McGill, Jr

Kathleen Born

Raymond G Dunham

A polypeptide and analogues thereof inhibit cholesteryl ester transfer protein (CETP). An anti-atherosclerosis composition comprises an anti-atherosclerosis effective amount of the polypeptide and a pharmaceutically-acceptable carrier. An anti-atherosclerosis kit comprises in separate sterile containers at least one unit of the composition containing the polypeptide, one syringe and one needle. An antibody has specificity for the polypeptide of the invention, the baboon CETP 4 kD polypeptide inhibitor, the 1-36 amino acid N-terminal fragment of apo C-I, modified apo A-I (MW: 31 kD) or modified apo E (MW: 41 kD). A method of preventing atherosclerosis in a mammal being predisposed to that condition comprises administering to the mammal a prophylactically effective amount of the polypeptide of the invention, and a method of treating a mammal afflicted with atherosclerosis comprises the administration of a therapeutically effective amount of the polypeptide disclosed herein.

CETP inhibitor polypeptide antibodies against the synthetic polypeptide

A polypeptide and analogues thereof inhibit cholesteryl ester transfer protein (CETP). An anti-atherosclerosis composition comprises an anti-atherosclerosis effective amount of the polypeptide and a pharmaceutically-acceptable carrier. An anti-atherosclerosis kit comprises in separate sterile containers at least one unit of the composition containing the polypeptide, one syringe and one needle. An antibody has specificity for the polypeptide of the invention, the baboon CETP 4kD polypeptide inhibitor, the 1-36 amino acid N-terminal fragment of apo C-I, modified apo A-I (MW:31kD) or modified apo E (MW:41kD). A method of preventing atherosclerosis in a mammal being predisposed to that condition comprises administering to the mammal a prophylactically effective amount of the polypeptide of the invention, and a method of treating a mammal afflicted with atherosclerosis comprises the administration of a therapeutically affective amount of the polypeptide disclosed herein.

Growing community of inventors

San Antonio, TX, United States of America

Rampratap Kushwaha